Omnipaque sales top half-billion mark

Article

Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505

Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505 million and was ranked 37th on thepublication's list.

The majority of Omnipaque's revenue derived from U.S. sales,which were pegged at $480 million in 1993 -- up 1% from the $475million in sales recorded the year before.

The next best selling imaging agent on the list was Bristol-MyersSquibb's Isovue. The x-ray imaging product recorded worldwidesales of $310 million in 1993, down 7.4% from the $335 millionregistered in 1992. Isovue had U.S. sales of $305 million in 1993and $320 million the year before.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.